Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer

Phase 1 Completed 30 enrolled National Cancer Centre, Singapore

Non-randomizedParallel-groupOpen-labelTreatment

The purpose of this study is to define the schedule and dose of oral vinorelbine (Navelbine) to be used with erlotinib in non-small cell lung cancer.

Evaluation	Drug	Modality	Dose	Route
Subject	Erlotinib	Small molecule	100 mg	Oral
Subject	Vinorelbine	Small molecule	40 mg/m2	Oral
Subject	Vinorelbine	Small molecule	80 mg/m2	Oral
Subject	Vinorelbine	Small molecule	100 mg	Oral
Subject	Vinorelbine	Small molecule	120 mg	Oral